Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 175

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START)

Open access
The JACCRO and KCSG Study Group, Koizumi, Wasaburo, Kim, Yeul Hong, Fujii, Masashi, Kim, Hoon Kyo, Imamura, Hiroshi, Lee, Kyung Hee, Hara, Takuo, Chung, Hyun Cheol, Satoh, Taroh, Cho, Jae Yong, Hosaka, Hisashi, Tsuji, Akihito, Takagane, Akinori, Inokuchi, Mikito, Tanabe, Kazuaki, Okuno, Tatsuya, Ogura, Mariko, Yoshida, Kazuhiro, Takeuchi, Masahiro, Nakajima, Toshifusa · 2014 · Journal of Cancer Research and Clinical Oncology

Abstract

PURPOSE: Cisplatin plus 5-fluorouracil has been globally accepted as a standard regimen for the treatment for advanced gastric cancer. However, cisplatin has several disadvantages, including renal toxicity and the need for admission. S-1 plus cisplatin has become a standard treatment for advanced gastric cancer in East Asia. This phase III study was designed to evaluate the potential benefits of adding docetaxel to S-1 without a platinum compound in patients with advanced gastric cancer. METHODS: Patients were randomly assigned to receive docetaxel plus S-1 or S-1 alone. The docetaxel plus S-1 group received docetaxel on day 1 and oral S-1 on days 1-14 of a 21-day cycle. The S-1 alone group received oral S-1 on days 1-28 of a 42-day cycle. The primary end point was overall survival. RESULTS: Of the 639 patients enrolled, 635 were eligible for analysis. The median overall survival was 12.5 months in the docetaxel plus S-1 group and 10.8 months in the S-1 alone group (p = 0.032). The median progression-free survival was 5.3 months in the docetaxel plus S-1 group and 4.2 months in the S-1 alone group (p = 0.001). As for adverse events, neutropenia was more frequent in the docetaxel plus S-1 group, but remained manageable. CONCLUSION: As first-line treatment for advanced gastric cancer, docetaxel plus S-1 significantly improves median overall and progression-free survival as compared with S-1 alone. (ClinicalTrials.gov number: NCT00287768).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00432-013-1563-5

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 175

Metadata

Authors
The JACCRO and KCSG Study Group, Koizumi, W., Kim, Y. H., Fujii, M., Kim, H. K., Imamura, H., Lee, K. H., Hara, T., Chung, H. C., Satoh, T., Cho, J. Y., Hosaka, H., Tsuji, A., Takagane, A., Inokuchi, M., Tanabe, K., Okuno, T., Ogura, M., Yoshida, K., Takeuchi, M., & Nakajima, T.
Venue
Journal of Cancer Research and Clinical Oncology
Published
2013-12-24
Volume
140
Issue
2
Pages
319-328
ISSN
  • 0084-5353 (ISSN-L)
  • 0171-5216
  • 1432-1335
OpenAlex
W2010681804
Cited by
175
References
1
FWCI
11.94
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). https://app.cochat.ai/papers/10.1007/s00432-013-1563-5
The paper
The JACCRO and KCSG Study Group, Koizumi, W., Kim, Y. H., Fujii, M., Kim, H. K., Imamura, H., Lee, K. H., Hara, T., Chung, H. C., Satoh, T., Cho, J. Y., Hosaka, H., Tsuji, A., Takagane, A., Inokuchi, M., Tanabe, K., Okuno, T., Ogura, M., Yoshida, K., . . . Nakajima, T. (2014). Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-013-1563-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.